Alc pts had similar age (56 vs 58), MELD (13 vs 13, p=0.8), %HE (50 vs 59%,p=0.4), ammonia (51 vs 49,p=0.8), sodium (136 each, p=0.9) compared to NAlc. MRS: There was a significantly higher

neuro-inflammation (high Glx/low mI) in alcoholics in Y-27632 clinical trial the anterior white (Glx 2.7 vs 2.4, mI 0.3 vs 0.5) & posterior gray (Glx 2.8 vs 2.5, mI 0.4 vs 0.5) matter. In both regions there was a significant positive correlation between MELD score & Glx (both r=0.4,p=0.0001) and negative with mI (both r=-0.6, p<0.0001). DTI: 56 cirrhotics (17 alc & 39 NAlc) underwent DTI. HE pts were similarly distributed (35% Alc & 41%NAlc). Alc pts had a significantly lower FA &higher MD indicating both interstitial and cytotoxic edema compared to NAlc in major white matter regions (corpus callosum, bilateral frontal white matter, right cingulum, and left inferior longitudinal and uncinate fasciculi). These white matter regions are important for neural network connectivity and implementing inhibitory control behaviors towards addictions There was no relationship between MELD score or HE with either FA or MD. Conclusions: Despite abstinence, there is continued neuro-in-flammation and widespread loss of integrity in large white matter tracts, especially between frontal lobes

and the rest of the brain, in alcoholic cirrhotics compared to the age and MELD-matched non-alcoholic cirrhotics. The reduced white matter integrity and increased diffusivity in alcoholic cirrhotics could Decitabine nmr worsen cognitive impairment independent of cirrhosis severity. Disclosures: Douglas M. Heuman – Consulting: Bayer, Grifols, Genzyme; Grant/Research Support: Exilixis, Novartis, Bayer, Bristol Myers Squibb, Scynexis, Ocera, Mann-kind, Salix, Globeimmune, Roche, SciClone, Wyeth, Otsuka, Ikaria, UCB, Cel-gene, Centocor, Millenium, Osiris; Speaking and Teaching: Otsuka, Astellas Richard K. Sterling – Advisory Committees or Review Panels: Merck, Vertex, Salix, Bayer, BMS, Abbott, medchemexpress Gilead; Grant/Research Support: Merck, Roche/Genen-tech, Pfizer, Gilead, Boehringer Ingelheim, Bayer, BMS, Abbott Velimir A. Luketic – Grant/Research Support: Intercept, Merck, Idenix, Vertex, Gilead,

BMS, Novartis, abbvie, Genfit, Takeda Arun J. Sanyal – Advisory Committees or Review Panels: Bristol Myers, Gilead, Abbott, Ikaria; Consulting: Salix, Immuron, Exhalenz, Nimbus, Genentech, Echo-sens, Takeda; Grant/Research Support: Salix, Genentech, Genfit, Intercept, Ikaria, Takeda, GalMed, Novartis, Gilead; Independent Contractor: UpToDate, Elsevier Puneet Puri – Advisory Committees or Review Panels: Health Diagnostic Laboratory Inc.; Consulting: NPS Pharmaceuticals Inc. Jasmohan S. Bajaj – Advisory Committees or Review Panels: Salix, Merz, otsuka, ocera, grifols, american college of gastroenterology; Grant/Research Support: salix, otsuka, grifols The following people have nothing to disclose: Vishwadeep Ahluwalia, James Wade, Scott Matherly, Mohammad S. Siddiqui, R.